Growth & profitability
- Revenue has declined 20.6% per year over the past 3 years.
WOK Financials WORK Medical Technology Group LTD
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | -$1M | 23.8% | 0.0% | $5M | — | $4M |
| 2024 | $12M | -$3M | 24.9% | 0.0% | -$11M | — | $7M |
| 2023 | $14M | $112030 | 30.5% | 0.0% | $2M | — | $2M |
| 2022 | $20M | $865210 | 22.4% | 0.0% | -$4M | — | $731178 |
Valuation over time
How the market has priced WOK against its own fundamentals since 2024-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 10.0× (Aug '24) to 6.5× (Jun '26).
P/E
P/S
Frequently asked questions
Is WOK growing its revenue and profit?
Over the past 3 years, WORK Medical Technology Group LTD's revenue has declined 20.6% per year. These are computed facts, not advice.
How much debt does WOK have?
As of FY2025, WORK Medical Technology Group LTD reported — of total debt against $4M of cash.
What is WOK's profit margin?
In FY2025, gross margin was 23.8%, operating margin —, and net margin -10.9%.
What is WOK's P/E ratio?
As of Jun '26, WORK Medical Technology Group LTD traded at a price-to-earnings ratio of about 1213.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.